Systematic Financial Management LP Lowers Stock Position in AngioDynamics, Inc. $ANGO

Systematic Financial Management LP trimmed its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 2.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,453,701 shares of the medical instruments supplier’s stock after selling 51,163 shares during the period. Systematic Financial Management LP owned approximately 0.06% of AngioDynamics worth $27,899,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Kotler Kevin acquired a new stake in AngioDynamics during the fourth quarter worth about $21,997,000. Weber Capital Management LLC ADV purchased a new stake in shares of AngioDynamics during the 4th quarter worth about $17,978,000. UBS Group AG increased its position in AngioDynamics by 83.6% during the 3rd quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock worth $12,315,000 after purchasing an additional 501,881 shares in the last quarter. Millennium Management LLC raised its holdings in AngioDynamics by 28.1% in the third quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after buying an additional 393,682 shares during the period. Finally, Nuveen LLC lifted its position in AngioDynamics by 40.5% during the fourth quarter. Nuveen LLC now owns 1,295,072 shares of the medical instruments supplier’s stock valued at $16,629,000 after buying an additional 373,110 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Stock Down 2.7%

ANGO opened at $13.44 on Friday. The firm has a market capitalization of $555.48 million, a P/E ratio of -15.45 and a beta of 0.34. The firm’s 50 day moving average is $12.47 and its 200-day moving average is $11.37. AngioDynamics, Inc. has a 52-week low of $8.36 and a 52-week high of $15.19.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. The business had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Equities analysts expect that AngioDynamics, Inc. will post -0.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Zacks Research cut shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. HC Wainwright raised their price objective on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Finally, Canaccord Genuity Group upped their target price on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, AngioDynamics currently has an average rating of “Hold” and an average price target of $19.50.

AngioDynamics Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.